For nearly a century, researchers have questioned how most adults develop immunity against Streptococcus pyogenes(Group A Streptococcus, GAS) despite the existence of more than 250 genetically distinct strains and relatively few clinically recognized infections during childhood. A new study published in Nature Communications provides evidence that repeated asymptomatic exposure to the bacterium may play a key role in building durable, strain-specific immunity, offering new insights into the natural history of GAS infection and host immune responses.¹
Streptococcus pyogenes is a major human pathogen responsible for common illnesses such as pharyngitis (strep throat) and impetigo. If inadequately treated, these infections can lead to severe immune-mediated complications, including acute rheumatic fever (ARF), rheumatic heart disease (RHD), and post-streptococcal glomerulonephritis. These complications remain a major public health concern in many low-resource settings, particularly among First Nations communities in Australia, where the burden of ARF and RHD is among the highest globally.²
Each year, approximately 10–20% of Australian children experience GAS pharyngitis, and recurrent infections frequently result in repeated antibiotic courses or tonsillectomy. However, despite relatively limited symptomatic infections, most adults eventually acquire protection against many circulating strains. The biological basis for this gradual accumulation of immunity has remained poorly understood because immune responses against one GAS strain generally do not confer protection against unrelated strains.
To investigate this paradox, researchers from Griffith University collaborated with the Murdoch Children's Research Institute (MCRI) and analysed immune responses from participants enrolled in a controlled human infection model. Healthy volunteers were deliberately exposed to a standardized inoculum of S. pyogenes that was sufficient to induce pharyngitis in most participants, while others remained completely asymptomatic. All volunteers received prompt antibiotic treatment after exposure to ensure participant safety.¹
The study produced an unexpected finding. Individuals who remained asymptomatic generated robust antibody responses comparable to those who developed clinical illness. More importantly, antibodies produced by asymptomatic participants demonstrated strong binding to the infecting GAS strain and effectively eliminated the organism in a murine model of tonsillitis, indicating that clinically silent exposure can induce functional, long-lasting protective immunity.¹
The investigators suggest that this mechanism helps explain why adults progressively acquire immunity throughout childhood. Previous epidemiological studies have shown that up to 30% of healthy individuals may carry GAS in the pharynx without symptoms. These subclinical colonization events may repeatedly stimulate the immune system, allowing individuals to gradually accumulate strain-specific antibodies over many years without experiencing overt disease.¹,³
Although these findings significantly advance understanding of natural immunity, they also highlight the complexity of developing an effective GAS vaccine. Because protective immunity appears largely strain-specific, reproducing natural protection through vaccination would require coverage against a very large number of circulating emm types, presenting a major scientific challenge. Consequently, the study is unlikely to provide an immediate vaccine strategy but offers valuable insights that may guide future vaccine development targeting conserved GAS antigens.¹,⁴
Beyond vaccine research, the findings have important public health implications. A better understanding of naturally acquired immunity could improve prevention strategies for severe post-streptococcal diseases such as ARF and RHD, particularly in populations disproportionately affected by these conditions. The research also raises the possibility that asymptomatic microbial exposure contributes to immune protection against other common bacterial pathogens, a concept warranting further investigation.
References
1. Pandey M, Lepletier A, Osowicki J, et al. Subclinical exposure to Streptococcus pyogenes drives the development of long-lived homologous immunity. Nature Communications. 2026.
2. World Health Organization. Group A Streptococcus and rheumatic heart disease. Geneva: WHO; 2023.
3. Shulman ST, Bisno AL, Clegg HW, et al. Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases. 2012;55(10):e86-e102.
4. Dale JB, Walker MJ. Update on Group A Streptococcal Vaccine Development. Current Opinion in Infectious Diseases. 2020;33(3):244-250.
Read more...